Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMX-110
- Development stage
- Phase 2
- Lead developer
- Immix Biopharma
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
IMX-110 is a clinical-stage, first-in-class Tissue-Specific Therapeutic (TST) platform candidate developed by Immix Biopharma. It consists of a nanoparticle-encapsulated combination of the chemotherapeutic doxorubicin and the poly-kinase inhibitor curcumin. This dual-action formulation is designed to normalize the tumor microenvironment (TME) by simultaneously inducing apoptosis in cancer cells and inhibiting pro-survival signaling pathways, including NF-kB, STAT3, and AKT. By "turning cold tumors hot," IMX-110 aims to overcome treatment resistance and enhance the efficacy of immune checkpoint inhibitors. The U.S. FDA has granted IMX-110 Orphan Drug Designation for soft tissue sarcoma and Rare Pediatric Disease Designation for rhabdomyosarcoma. It is currently being evaluated in Phase 1/2a clinical trials for various advanced solid tumors, both as a monotherapy and in combination with the anti-PD-1 antibody tislelizumab.
- Other names
- curcumin/doxorubicin-encapsulating nanoparticle IMX-110
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)STAT3 (Signal Transducer and Activator of Transcription 3)TOP2A (DNA topoisomerase II)NF-κBDNA
Beyond the preview
Go deeper on IMX-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMX-110.